Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

AbbVie and Roche's leukaemia drug venetoclax nears EU market

AbbVie and Roche's leukaemia drug venetoclax nears EU market It is also being tested in combination with Roche's $7bn brand MabThera/Rituxan (rituximab), which is widely-used for CLL, as well as Imbruvica which also cleared $1.2bn in

AbbVie's venetoclax set for early access in UK

AbbVie's venetoclax set for early access in UK up indications such as first-line CLL, combination CLL therapy with Roche's MabThera/Rituxan (rituximab), non-Hodgkin's lymphoma (NHL), acute myeloid leukaemia (AML) and multiple myeloma.

Roche says Tecentriq "off to a good start"

Roche says Tecentriq Roche's top-selling drug MabThera/Rituxan (rituximab) - approved for several indications including non-Hodgkin's lymphoma and CLL - also managed a 4% increase to 3.7bn francs. .

Roche's Gazyvaro flunks trial in non-Hodgkin's lymphoma

Roche's Gazyvaro flunks trial in non-Hodgkin's lymphoma Failed to improve progression-free survival when compared with its MabThera/Rituxan therapy. ... Two previous studies showed Gazyva/Gazyvaro helped people with previously untreated FL or CLL live longer without their disease worsening compared to MabThera

Novartis gets FDA panel backing for biosimilar Enbrel

Novartis gets FDA panel backing for biosimilar Enbrel The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics